One platform for all researcher needs
AI-powered academic writing assistant
Your #1 AI companion for literature search
AI tool for graphics, illustrations, and artwork
Unlock unlimited use of all AI tools with the Editage All Access membership.
Explore Editage All Accesshttps://doi.org/10.1182/blood.v118.21.109.109
Copy DOI Journal: Blood |  Publication Date: Nov 18, 2011 |
 Citations: 32 |
Affiliation: The University of Texas MD Anderson Cancer Center, Singapore General Hospital, Duke-NUS Medical School, Ariadne Diagnostics (United States), SunEdison (United States), Ronald Reagan UCLA Medical Center, University of California, Los Angeles, Michigan Center for Translational Pathology, University of Michigan–Ann Arbor, Washington University in St. Louis, St. Eugenio Hospital, Dana-Farber Cancer Institute, Policlinico S.Orsola-Malpighi, University of Milano-Bicocca, Azienda Ospedaliera San Gerardo, Hôpital Saint-Louis, Hôpital Edouard Herriot, Charité - Universitätsmedizin Berlin, Seoul St. Mary's Hospital, Catholic University of Korea, Moffitt Cancer Center, Hammersmith Hospital, Imperial College London, Emory HealthcareInitial Findings From the PACE Trial: A Pivotal Phase 2 Study of Ponatinib in Patients with CML and Ph+ ALL Resistant or Intolerant to Dasatinib or Nilotinib, or with the T315I Mutation
Sign-in/Register to access full text options 
Free) Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
